23Dec 2022
Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and often fatal disorder. Using an in silico data-driven approach, we identified a robust connection between the transcriptomic perturbations in IPF disease and those induced by saracatinib; a selective Src kinase inhibitor developed initially for oncological indications. In addition, these studies identify novel Src-dependent fibrogenic pathways and support the investigation of the therapeutic effectiveness of saracatinib in IPF treatment.

  • #critical care

Like

Save

Share